miRNA Mimics: Developing nanomedicines that deliver miRNA mimics (e.g., miR-335, miR-379-5p) to restore their natural inhibition of KIF4A has the potential to reduce tumour growth by 35%-50% in models such as breast cancer. This evidence concerns the gene KIF4A and breast carcinoma.